文献速递遗传性与小管间质肾病肾小球疾病

人诱导多能干细胞与肾脏类器官模型揭示胱氨酸病联合治疗新策略

Use of Human Induced Pluripotent Stem Cells and Kidney Organoids To Develop a Cysteamine/mTOR Inhibition Combination Therapy for Cystinosis.
PubMed 文献 · J Am Soc Nephrol · 2020-03-20

研究利用人诱导多能干细胞(iPSC)和肾脏类器官构建胱氨酸病模型,发现其表现为胱氨酸蓄积、凋亡增加和基础自噬缺陷。半胱胺可改善部分表型,依维莫司可减少大溶酶体、降低凋亡并激活自噬,但两者单用均不能纠正全部异常;联合使用可纠正所有观察到的表型异常,提示联合治疗潜力。

要点

  • 胱氨酸病iPSC及类器官模型重现胱氨酸蓄积、凋亡增加和自噬缺陷。
  • 半胱胺单药不能纠正凋亡和基础自噬异常。
  • 半胱胺联合依维莫司可纠正所有观察到的表型异常。

核心结论

  • 半胱胺与mTOR抑制剂依维莫司联合使用可纠正胱氨酸病iPSC和肾脏类器官模型的所有表型异常,有望改善胱氨酸病治疗。

研究设计与样本

  • 研究构建了首个人诱导多能干细胞(iPSC)和肾脏类器官的胱氨酸病模型,并比较了模型与对照组的表型差异。

主要发现

  • 与对照组相比,胱氨酸病模型表现出胱氨酸水平升高、凋亡增加和基础自噬缺陷。
  • 半胱胺治疗可改善表型,但凋亡和基础自噬异常未纠正。
  • 依维莫司可减少大溶酶体数量、降低凋亡并激活自噬,但不能挽救胱氨酸加载缺陷。
  • 半胱胺与依维莫司联合处理可纠正所有观察到的表型异常。

临床怎么用

  • 对于胱氨酸病患者,在半胱胺治疗基础上联合mTOR抑制剂可能更全面改善细胞表型,但需临床研究验证。

局限性

  • 研究基于iPSC和肾脏类器官体外模型,尚未在患者或动物模型中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mutations in CTNS-a gene encoding the cystine transporter cystinosin-cause the rare, autosomal, recessive, lysosomal-storage disease cystinosis. Research has also implicated cystinosin in modulating the mTORC1 pathway, which serves as a core regulator of cellular metabolism, proliferation, survival, and autophagy. In its severest form, cystinosis is characterized by cystine accumulation, renal proximal tubule dysfunction, and kidney failure. Because treatment with the cystine-depleting drug cysteamine only slows disease progression, there is an urgent need for better treatments. METHODS: To address a lack of good human-based cell culture models for studying cystinosis, we generated the first human induced pluripotent stem cell (iPSC) and kidney organoid models of the disorder. We used a variety of techniques to examine hallmarks of cystinosis-including cystine accumulation, lysosome size, the autophagy pathway, and apoptosis-and performed RNA sequencing on isogenic lines to identify differentially expressed genes in the cystinosis models compared with controls. RESULTS: Compared with controls, these cystinosis models exhibit elevated cystine levels, increased apoptosis, and defective basal autophagy. Cysteamine treatment ameliorates this phenotype, except for abnormalities in apoptosis and basal autophagy. We found that treatment with everolimus, an inhibitor of the mTOR pathway, reduces the number of large lysosomes, decreases apoptosis, and activates autophagy, but it does not rescue the defect in cystine loading. However, dual treatment of cystinotic iPSCs or kidney organoids with cysteamine and everolimus corrects all of the observed phenotypic abnormalities. CONCLUSIONS: These observations suggest that combination therapy with a cystine-depleting drug such as cysteamine and an mTOR pathway inhibitor such as everolimus has potential to improve treatment of cystinosis.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Hollywood JA, Przepiorski A, D'Souza RF, et al. Use of Human Induced Pluripotent Stem Cells and Kidney Organoids To Develop a Cysteamine/mTOR Inhibition Combination Therapy for Cystinosis. J Am Soc Nephrol. 2020. PMID: 32198276. doi:10.1681/ASN.2019070712

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。